The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adverum Biotechnologies, Inc. Common Stock 00773U108 4,815 5,068,233 SH   OTR   0 5,068,233 0
Aligos Therapeutics, Inc. Common Stock 01626L105 2,552 2,320,381 SH   OTR   0 2,320,381 0
Clovis Oncology, Inc. Common Stock 189464100 121 101,855 SH   OTR   0 101,855 0
CRISPR Therapeutics AG Common Shares H17182108 32,581 498,558 SH   OTR   0 498,558 0
CymaBay Therapeutics, Inc. Common Stock 23257D103 1,903 543,753 SH   OTR   0 543,753 0
Gritstone Oncology, Inc. Common Stock 39868T105 9,152 3,561,150 SH   OTR   0 3,561,150 0
Minerva Surgical Inc. Common Stock 60343F106 1,331 1,673,700 SH   OTR   0 1,673,700 0
Passage Bio, Inc. Common Stock 702712100 6,200 4,959,769 SH   OTR   0 4,959,769 0